Nov 16, 2022 / 06:15PM GMT
Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
With me is Pushkal Garg, the Chief Medical Officer; and Rena Denoncourt, Head of the TTR program, and we're all reminiscing over a great dinner we had last night. So with that, everyone knows the story. There's no need to really set the stage. I think it would be good to talk about TTR and maybe relitigate a little bit of our conversation yesterday.
Questions and Answers:
Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior AnalystJust related to sort of Helios-B what you're observing in the trial in terms of event rates and what Alnylam's reaction is to a competitor study for Ionis and AstraZeneca functionally being now twice the size because what they're saying is they need that for powering based on how the disease has changed. What's your confidence in your trial and your reaction of what's been going on?
Pushkal P.
Trustpilot
